What is Celldex Therapeutics's R&D?

Celldex Therapeutics (CLDX) reported R&D of $73M in Q1 2026.

How has Celldex Therapeutics's R&D changed year-over-year?

Celldex Therapeutics's R&D increased by 38.7% year-over-year, from $52.61M to $73M.

What is the long-term trend for Celldex Therapeutics's R&D?

Over 4 years (2021 to 2025), Celldex Therapeutics's R&D has grown at a 46.4% compound annual growth rate (CAGR), from $53.31M to $245.07M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Celldex Therapeutics CLDX R&D

R&D at other companies

Eli LillyLLY

$3.51B+28.4%

Rogers CorporationROG

$6.7M-5.6%

AmgenAMGN

$1.72B+15.7%

Regeneron PharmaceuticalsREGN

$1.54B+16.3%

IncyteINCY

$515.9M+18.0%

Arcutis Biotherapeutics, Inc.ARQT

$30.63M+74.6%

Segments

By segment

See full

Single Reportable$73M+38.7%

Other financials

Income statement

See full

Revenue$15.0K-97.8%

Operating income-$84.4M-34.6%

Net income-$78.7M-46.3%

EPS (diluted)-$1.18-45.7%

Balance sheet

See full

Cash & equivalents$35.7M+109%

Total debt$1.9M-44.3%

Total equity$456.2M-35.1%

Total assets$511.3M-30.9%

Cash flow

See full

Operating cash flow-$65.6M-20.6%

CapEx$1.6M+518%

Free cash flow-$67.2M-23.0%

Valuation

See full

Market cap$2.59B+75.2%

Enterprise value$2.55B+74.4%

P/S2,989.2×+2,794×

Profitability

See full

Operating margin-35,688.5%-39,114pp

Net margin-32,753.6%-35,519pp

FCF margin-26,125.8%-28,907pp

Returns & leverage

See full

Return on equity-48.9%-498pp

Debt / equity0×0.0×

Current ratio8.9×-12.7×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Celldex Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Celldex Therapeutics's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Celldex Therapeutics's R&D?: Celldex Therapeutics (CLDX) reported R&D of $73M in Q1 2026.
How has Celldex Therapeutics's R&D changed year-over-year?: Celldex Therapeutics's R&D increased by 38.7% year-over-year, from $52.61M to $73M.
What is the long-term trend for Celldex Therapeutics's R&D?: Over 4 years (2021 to 2025), Celldex Therapeutics's R&D has grown at a 46.4% compound annual growth rate (CAGR), from $53.31M to $245.07M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.